Pacira BioSciences Stock Price Target and Analyst Ratings (NASDAQ:PCRX)

Analyst Price Target for PCRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$77.50

▲ +22.88% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $77.50, with a high forecast of $94.00 and a low forecast of $48.00. The average price target represents a 22.88% upside from the last price of $63.07.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in Pacira BioSciences. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/25/2019

0 strong buy ratings
8 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/23/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

4/22/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

7/21/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/19/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/17/2021

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/17/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/15/2021	Berenberg Bank	Initiated Coverage	Buy	$93.00	High	i
4/9/2021	Berenberg Bank	Initiated Coverage	Buy	$93.00	Low	i
3/8/2021	HC Wainwright	Boost Price Target	Buy	$70.00 ➝ $86.00	Medium	i
3/1/2021	HC Wainwright	Boost Price Target	Buy	$70.00 ➝ $86.00	Low	i
2/26/2021	Barclays	Boost Price Target	Overweight	$79.00 ➝ $94.00	Medium	i
2/11/2021	Northland Securities	Downgrade	Outperform ➝ Market Perform	$72.00 ➝ $75.00	Low	i
1/25/2021	Northland Securities	Boost Price Target	Outperform	$67.00 ➝ $72.00	Medium	i
1/21/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$63.00 ➝ $75.00	High	i Rating by A. Fadia at SVB Leerink LLC
1/20/2021	Piper Sandler	Boost Price Target	Overweight	$65.00 ➝ $90.00	Low	i
1/8/2021	Needham & Company LLC	Boost Price Target	Buy	$67.00 ➝ $76.00	High	i
1/6/2021	Royal Bank of Canada	Boost Price Target	Outperform	$65.00 ➝ $70.00	N/A	i
12/14/2020	Barclays	Boost Price Target	Overweight	$73.00 ➝ $79.00	Low	i
12/9/2020	Needham & Company LLC	Lower Price Target	Buy	$68.00 ➝ $67.00	High	i
11/2/2020	Wedbush	Lower Price Target	Outperform	$85.00 ➝ $83.00	Low	i Rating by Liana Moussatos at Wedbush
10/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium	i Rating by Liana Moussatos at Wedbush
9/30/2020	Jefferies Financial Group	Boost Price Target		$69.00 ➝ $75.00	Low	i
9/21/2020	Northland Securities	Upgrade	Market Perform ➝ Outperform	$58.00 ➝ $67.00	Medium	i
9/9/2020	Needham & Company LLC	Boost Price Target	Buy	$64.00 ➝ $68.00	High	i
8/17/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium	i Rating by Liana Moussatos at Wedbush
8/14/2020	Truist	Boost Price Target		$54.00 ➝ $65.00	Low	i
8/10/2020	HC Wainwright	Boost Price Target	Buy	$68.00 ➝ $70.00	High	i Rating by Oren Livnat at HC Wainwright
7/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low	i Rating by Liana Moussatos at Wedbush
7/13/2020	HC Wainwright	Reiterated Rating	Buy	$63.00 ➝ $68.00	High	i
7/10/2020	Jefferies Financial Group	Boost Price Target	Buy	$53.00 ➝ $69.00	Low	i
7/6/2020	Needham & Company LLC	Boost Price Target	Buy	$52.00 ➝ $64.00	Medium	i
7/6/2020	Piper Sandler	Boost Price Target	Positive ➝ Overweight	$49.00 ➝ $65.00	Medium	i Rating by David Amsellem at Piper Sandler
7/2/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A	i Rating by Liana Moussatos at Wedbush
7/1/2020	Royal Bank of Canada	Boost Price Target	Outperform	$56.00 ➝ $62.00	High	i
6/30/2020	SVB Leerink	Boost Price Target	Outperform	$45.00 ➝ $58.00	Medium	i Rating by A. Fadia at SVB Leerink LLC
6/30/2020	Northland Securities	Boost Price Target	Market Perform	$50.00 ➝ $54.00	Low	i
5/27/2020	Northland Securities	Downgrade	Outperform ➝ Market Perform		Low	i
5/26/2020	Guggenheim	Initiated Coverage	Neutral		Low	i
5/13/2020	Royal Bank of Canada	Reiterated Rating	Buy	$56.00	High	i
5/12/2020	Wedbush	Reiterated Rating	Buy	$85.00	High	i Rating by Liana Moussatos at Wedbush
5/8/2020	SVB Leerink	Boost Price Target	Buy	$44.00 ➝ $45.00	Medium	i Rating by A. Fadia at SVB Leerink LLC
5/7/2020	Stifel Nicolaus	Lower Price Target	Hold	$49.00 ➝ $48.00	Low	i Rating by Derek Archila at Stifel Nicolaus
4/30/2020	Needham & Company LLC	Lower Price Target	Buy	$56.00 ➝ $52.00	High	i
4/27/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium	i Rating by Liana Moussatos at Wedbush
4/17/2020	Northland Securities	Reiterated Rating	Buy	$50.00	High	i
4/7/2020	Northland Securities	Initiated Coverage	Outperform	$50.00	High	i
3/23/2020	Piper Sandler	Lower Price Target		$60.00 ➝ $49.00	High	i Rating by David Amsellem at Piper Sandler
3/23/2020	Royal Bank of Canada	Lower Price Target	Outperform	$65.00 ➝ $56.00	High	i
3/20/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $44.00	High	i Rating by A. Fadia at SVB Leerink LLC
2/24/2020	HC Wainwright	Boost Price Target	Buy	$60.00 ➝ $63.00	Medium	i
2/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A	i Rating by Liana Moussatos at Wedbush
2/20/2020	Stifel Nicolaus	Reiterated Rating	Hold	$49.00	High	i
2/20/2020	Piper Sandler	Boost Price Target	Buy	$54.00 ➝ $60.00	Low	i
1/23/2020	SunTrust Banks	Initiated Coverage	Buy	$60.00	Low	i
1/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low	i Rating by Liana Moussatos at Wedbush
12/18/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low	i
12/17/2019	Wedbush	Reiterated Rating	Buy	$85.00	Medium	i Rating by Liana Moussatos at Wedbush
11/8/2019	Barclays	Boost Price Target	Overweight	$52.00 ➝ $55.00	Medium	i Rating by Balaji Prasad at Barclays PLC
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$56.00	High	i
11/7/2019	Cowen	Reiterated Rating	Hold	$41.00	High	i
11/6/2019	BTIG Research	Initiated Coverage	Buy	$56.00 ➝ $56.00	Medium	i
10/8/2019	Jefferies Financial Group	Set Price Target	Buy	$60.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
8/9/2019	Stifel Nicolaus	Set Price Target	Hold	$42.00	Low	i Rating by Derek Archila at Stifel Nicolaus
8/9/2019	BMO Capital Markets	Lower Price Target	Market Perform	$46.00 ➝ $43.00	Low	i Rating by Gary Nachman at BMO Capital Markets
6/28/2019	Wedbush	Set Price Target	Buy	$85.00	Medium	i Rating by Liana Moussatos at Wedbush
6/12/2019	Wedbush	Reiterated Rating	Outperform	$85.00	Low	i Rating by Liana Moussatos at Wedbush
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$52.00	Low	i
5/6/2019	Mizuho	Upgrade	Underperform ➝ Neutral	$29.00 ➝ $38.00	Low	i
5/3/2019	BMO Capital Markets	Set Price Target	Hold	$46.00	Low	i Rating by Gary Nachman at BMO Capital Markets
5/2/2019	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$45.00	Low	i Rating by Derek Archila at Stifel Nicolaus
4/9/2019	Piper Jaffray Companies	Set Price Target	Buy	$55.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
3/8/2019	Wedbush	Reiterated Rating	Outperform	$85.00	Low	i Rating by Liana Moussatos at Wedbush
3/8/2019	Stifel Nicolaus	Reiterated Rating	Positive ➝ Sell	$33.00	Low	i
3/1/2019	BMO Capital Markets	Set Price Target	Hold	$44.00	Medium	i Rating by Gary Nachman at BMO Capital Markets
3/1/2019	Cowen	Reiterated Rating	Hold		Low	i
2/12/2019	National Securities	Initiated Coverage	Sell		Medium	i
2/1/2019	Mizuho	Downgrade	Neutral ➝ Underperform		High	i
1/29/2019	Wedbush	Set Price Target	Buy	$91.00	High	i Rating by Liana Moussatos at Wedbush
11/5/2018	Wedbush	Set Price Target	Buy	$85.00 ➝ $90.00	Low	i Rating by Liana Moussatos at Wedbush
11/5/2018	Mizuho	Boost Price Target	Neutral	$46.00	Medium	i
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $50.00	Low	i
11/2/2018	Jefferies Financial Group	Boost Price Target	Buy	$60.00	Low	i
11/2/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$40.00 ➝ $47.00	Low	i
11/2/2018	Royal Bank of Canada	Set Price Target	Buy	$60.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
11/2/2018	HC Wainwright	Boost Price Target	Buy	$60.00	High	i Rating by Oren Livnat at HC Wainwright
11/1/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Buy	$56.00 ➝ $63.00	High	i Rating by Donald Ellis at JMP Securities
11/1/2018	Needham & Company LLC	Set Price Target	Buy	$60.00	High	i Rating by Serge Belanger at Needham & Company LLC
11/1/2018	Piper Jaffray Companies	Set Price Target	Buy	$55.00	High	i Rating by David Amsellem at Piper Jaffray Companies
11/1/2018	Mizuho	Reiterated Rating	Hold	$43.00	High	i
10/10/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $48.00	High	i
10/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$51.00	High	i Rating by David Amsellem at Piper Jaffray Companies
10/2/2018	Canaccord Genuity	Set Price Target	Hold ➝ Hold	$45.00 ➝ $49.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
9/19/2018	Royal Bank of Canada	Set Price Target	Buy	$55.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
9/13/2018	Stifel Nicolaus	Initiated Coverage	Sell	$41.00	Low	i
9/4/2018	Canaccord Genuity	Set Price Target	Hold	$45.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
8/17/2018	Canaccord Genuity	Reiterated Rating	Hold	$45.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
8/6/2018	Barclays	Boost Price Target	Overweight ➝ Buy	$40.00 ➝ $50.00	Low	i Rating by Douglas Tsao at Barclays PLC
8/6/2018	Wedbush	Reiterated Rating	Outperform	$85.00 ➝ $80.00	Low	i Rating by Liana Moussatos at Wedbush
8/6/2018	Wedbush	Set Price Target	Outperform ➝ Outperform	$85.00	Low	i Rating by Liana Moussatos at Wedbush
8/6/2018	Bank of America	Downgrade	Buy ➝ Neutral		Low	i
8/3/2018	Needham & Company LLC	Upgrade	Hold ➝ Buy	$54.00	High	i Rating by Serge Belanger at Needham & Company LLC
8/3/2018	HC Wainwright	Reiterated Rating	Buy	$52.00	High	i Rating by Oren Livnat at HC Wainwright
8/2/2018	Piper Jaffray Companies	Set Price Target	Buy	$48.00	High	i Rating by David Amsellem at Piper Jaffray Companies
8/2/2018	Royal Bank of Canada	Set Price Target	Buy	$50.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
8/2/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Neutral	$40.00	High	i
7/30/2018	Canaccord Genuity	Reiterated Rating	Hold	$34.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
7/26/2018	HC Wainwright	Set Price Target	Buy	$48.00	High	i Rating by Oren Livnat at HC Wainwright
7/10/2018	Cowen	Reiterated Rating	Hold		Medium	i
7/10/2018	HC Wainwright	Reiterated Rating	Buy	$48.00	Medium	i Rating by Oren Livnat at HC Wainwright
6/29/2018	Canaccord Genuity	Set Price Target	Hold	$34.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
6/29/2018	Mizuho	Reiterated Rating	Hold	$31.00	Low	i
5/30/2018	Canaccord Genuity	Set Price Target	Hold	$34.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
5/17/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/11/2018	Canaccord Genuity	Set Price Target	Hold	$34.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
5/4/2018	JMP Securities	Set Price Target	Outperform ➝ Buy	$65.00 ➝ $56.00	Medium	i
5/3/2018	Canaccord Genuity	Set Price Target	Hold	$34.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
5/3/2018	Mizuho	Reiterated Rating	Hold	$31.00	Medium	i
5/3/2018	HC Wainwright	Set Price Target	Buy	$48.00	Low	i Rating by Oren Livnat at HC Wainwright
4/30/2018	Wedbush	Reiterated Rating	Outperform	$80.00	Medium	i
4/10/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$40.00 ➝ $43.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
4/9/2018	Wedbush	Lower Price Target	Outperform	$72.00 ➝ $80.00	High	i
4/9/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$31.00 ➝ $34.00	Low	i
4/9/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Hold	$40.00 ➝ $43.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
4/9/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $48.00	Medium	i Rating by Oren Livnat at HC Wainwright
4/9/2018	Piper Jaffray Companies	Set Price Target	Buy	$44.00	Medium	i Rating by David Amsellem at Piper Jaffray Companies
4/9/2018	Canaccord Genuity	Boost Price Target	Hold ➝ Hold	$32.00 ➝ $34.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
4/8/2018	Seaport Global Securities	Set Price Target	Buy	$48.00	Medium	i Rating by Corey Davis at Seaport Global Securities
3/21/2018	Mizuho	Lower Price Target	Neutral ➝ Neutral	$44.00 ➝ $31.00	High	i
3/20/2018	Seaport Global Securities	Reiterated Rating	Positive ➝ Buy	$42.00	Medium	i
3/1/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$32.00 ➝ $31.00	Medium	i
3/1/2018	Royal Bank of Canada	Set Price Target	Buy	$44.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
3/1/2018	HC Wainwright	Set Price Target	Buy	$45.00	High	i Rating by Oren Livnat at HC Wainwright
3/1/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
2/16/2018	Needham & Company LLC	Downgrade	Buy ➝ Hold	$55.00	High	i Rating by Serge Belanger at Needham & Company LLC
2/16/2018	Barclays	Reiterated Rating	Buy	$40.00	High	i
2/16/2018	Canaccord Genuity	Reiterated Rating	Hold	$32.00	High	i Rating by Dewey Steadman at Canaccord Genuity
2/15/2018	BMO Capital Markets	Lower Price Target	Market Perform	$41.00 ➝ $32.00	High	i
2/15/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
2/13/2018	Piper Jaffray Companies	Set Price Target	Buy	$49.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
1/30/2018	Canaccord Genuity	Lower Price Target	Hold ➝ Hold	$46.00 ➝ $42.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
1/19/2018	Seaport Global Securities	Initiated Coverage	Buy ➝ Buy	$50.00	Low	i
1/5/2018	Wedbush	Reiterated Rating	Buy		Low	i
1/4/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$52.00 ➝ $55.00	Low	i Rating by Oren Livnat at HC Wainwright
1/4/2018	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low	i Rating by Chris Schott at JPMorgan Chase & Co.
1/4/2018	Canaccord Genuity	Set Price Target	Buy ➝ Buy	$42.00 ➝ $46.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
1/4/2018	Royal Bank of Canada	Set Price Target	Buy	$54.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$46.00	Low	i Rating by A. Fadia at SVB Leerink LLC
12/29/2017	Canaccord Genuity	Set Price Target	Hold	$42.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
12/20/2017	Wedbush	Reiterated Rating	Buy	$80.00	Low	i
12/18/2017	JPMorgan Chase & Co.	Initiated Coverage	Neutral ➝ Neutral	$47.00	High	i Rating by Chris Schott at JPMorgan Chase & Co.
11/29/2017	Canaccord Genuity	Set Price Target	Hold	$42.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
11/29/2017	Mizuho	Downgrade	Buy ➝ Neutral	$53.00 ➝ $44.00	Medium	i
11/20/2017	Wedbush	Reiterated Rating	Buy	$80.00	N/A	i
11/16/2017	Janney Montgomery Scott	Set Price Target	Sell	$27.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
11/9/2017	Canaccord Genuity	Boost Price Target	Hold	$33.00 ➝ $38.00	N/A	i Rating by Dewey Steadman at Canaccord Genuity
11/9/2017	Oppenheimer	Reiterated Rating	Hold		N/A	i
11/9/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$52.00	N/A	i Rating by Corey Davis at HC Wainwright
11/9/2017	Jefferies Financial Group	Lower Price Target	Buy	$52.00	N/A	i
11/8/2017	BMO Capital Markets	Boost Price Target	Market Perform	$38.00 ➝ $39.00	N/A	i
10/30/2017	Canaccord Genuity	Downgrade	Buy ➝ Hold	$44.00 ➝ $33.00	N/A	i Rating by Dewey Steadman at Canaccord Genuity
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$55.00	N/A	i
10/26/2017	Janney Montgomery Scott	Downgrade	Neutral ➝ Sell	$27.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
10/25/2017	Wedbush	Reiterated Rating	Outperform	$87.00	N/A	i
10/19/2017	Needham & Company LLC	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $52.00	N/A	i Rating by Serge Belanger at Needham & Company LLC
10/13/2017	Royal Bank of Canada	Reiterated Rating	Buy	$54.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/4/2017	Bank of America	Lower Price Target	Buy	$46.00 ➝ $45.00	Low	i
10/1/2017	Canaccord Genuity	Reiterated Rating	Buy	$48.00 ➝ $44.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$41.00	Medium	i
9/26/2017	Needham & Company LLC	Reiterated Rating	Buy		Low	i Rating by Serge Belanger at Needham & Company LLC
9/25/2017	Mizuho	Reiterated Rating	Buy	$53.00	Medium	i
9/7/2017	Jefferies Financial Group	Reiterated Rating	Buy	$59.00	Medium	i Rating by David Steinberg at Jefferies Financial Group Inc.
9/7/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		Low	i
9/7/2017	Oppenheimer	Initiated Coverage	Market Perform		Medium	i
9/6/2017	UBS Group	Initiated Coverage	Market Perform		Medium	i
9/5/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$54.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
8/29/2017	Canaccord Genuity	Lower Price Target	Buy	$56.00 ➝ $48.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
8/23/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Medium	i
8/22/2017	Mizuho	Reiterated Rating	Buy	$54.00 ➝ $53.00	Low	i
8/22/2017	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$55.00	Low	i
8/21/2017	Janney Montgomery Scott	Upgrade	Sell ➝ Neutral	$31.00	Low	i Rating by Ken Trbovich at Janney Montgomery Scott
8/3/2017	BMO Capital Markets	Lower Price Target	Market Perform	$42.00 ➝ $40.00	Low	i
8/3/2017	HC Wainwright	Set Price Target	Buy	$59.00	Medium	i Rating by Corey Davis at HC Wainwright
8/2/2017	Cowen	Reiterated Rating	Hold		Medium	i Rating by Boris Peaker at Cowen Inc
7/31/2017	Canaccord Genuity	Reiterated Rating	Buy	$56.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
7/30/2017	Royal Bank of Canada	Set Price Target	Buy	$58.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
7/26/2017	Mizuho	Reiterated Rating	Buy	$54.00	Medium	i
7/25/2017	Canaccord Genuity	Set Price Target	Buy	$56.00	High	i Rating by Dewey Steadman at Canaccord Genuity
7/19/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Low	i
7/14/2017	Cowen	Reiterated Rating	Hold		Low	i Rating by Boris Peaker at Cowen Inc
6/27/2017	Royal Bank of Canada	Set Price Target	Buy	$58.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
6/21/2017	Wedbush	Reiterated Rating	Outperform	$87.00	High	i
5/24/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Low	i
5/22/2017	Canaccord Genuity	Set Price Target	Buy	$60.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
5/15/2017	Royal Bank of Canada	Set Price Target	Buy	$58.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
5/15/2017	Canaccord Genuity	Reiterated Rating	Buy	$60.00	Low	i
5/6/2017	HC Wainwright	Set Price Target	Buy	$59.00	Low	i Rating by Corey Davis at HC Wainwright
5/5/2017	Canaccord Genuity	Reiterated Rating	Buy	$60.00	Low	i
5/5/2017	Mizuho	Lower Price Target	Buy ➝ Buy	$57.00 ➝ $54.00	Medium	i
4/19/2017	Wedbush	Reiterated Rating	Outperform	$89.00	Medium	i
4/13/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$58.00	Medium	i
4/4/2017	Jefferies Financial Group	Set Price Target	Buy	$60.00	Medium	i Rating by David Steinberg at Jefferies Financial Group Inc.
3/29/2017	Canaccord Genuity	Reiterated Rating	Buy	$60.00	Low	i
3/23/2017	Mizuho	Lower Price Target	Buy	$59.00 ➝ $54.00	High	i
3/22/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $89.00	High	i
3/21/2017	Barclays	Reiterated Rating	Overweight ➝ Overweight	$54.00 ➝ $59.00	High	i
3/20/2017	SVB Leerink	Reiterated Rating	Market Perform		High	i
3/16/2017	HC Wainwright	Set Price Target	Buy	$59.00	High	i Rating by Corey Davis at HC Wainwright
3/14/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$60.00	Medium	i
3/3/2017	Mizuho	Boost Price Target	Buy	$59.00	N/A	i
3/2/2017	Jefferies Financial Group	Set Price Target	Buy	$60.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
3/2/2017	Cowen	Reiterated Rating	Hold		N/A	i Rating by Boris Peaker at Cowen Inc
3/2/2017	Janney Montgomery Scott	Downgrade	Neutral ➝ Sell	$38.00	N/A	i
3/2/2017	HC Wainwright	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $59.00	N/A	i Rating by Corey Davis at HC Wainwright
3/2/2017	Wedbush	Reiterated Rating	Outperform	$89.00	N/A	i
3/2/2017	BMO Capital Markets	Reiterated Rating	Hold	$45.00	N/A	i
2/22/2017	Wedbush	Reiterated Rating	Outperform		N/A	i
2/21/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$55.00	N/A	i
2/8/2017	Wedbush	Reiterated Rating	Outperform	$89.00	N/A	i
2/2/2017	Jefferies Financial Group	Set Price Target	Buy	$53.00	N/A	i Rating by David Steinberg at Jefferies Financial Group Inc.
1/28/2017	Mizuho	Reiterated Rating	Buy	$41.00 ➝ $50.00	N/A	i
1/25/2017	Wedbush	Reiterated Rating	Outperform	$89.00	N/A	i
1/25/2017	Cowen	Reiterated Rating	Hold		N/A	i Rating by Boris Peaker at Cowen Inc
1/25/2017	HC Wainwright	Set Price Target	Buy	$46.00 ➝ $48.00	N/A	i Rating by Corey Davis at HC Wainwright
1/10/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$35.00	N/A	i
1/9/2017	Mizuho	Reiterated Rating	Buy	$41.00	N/A	i
1/5/2017	Wedbush	Reiterated Rating	Outperform	$89.00	N/A	i
1/3/2017	HC Wainwright	Initiated Coverage	Buy	$43.00	N/A	i
12/30/2016	Janney Montgomery Scott	Boost Price Target	Neutral	$31.00 ➝ $34.00	N/A	i
12/21/2016	Wedbush	Reiterated Rating	Outperform	$89.00	N/A	i
12/21/2016	Mizuho	Lower Price Target	Buy	$46.00 ➝ $41.00	N/A	i
12/7/2016	Jefferies Financial Group	Reiterated Rating	Buy	$53.00	N/A	i
12/2/2016	Janney Montgomery Scott	Initiated Coverage	Neutral	$31.00	N/A	i
12/1/2016	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Neutral	$36.00	N/A	i
11/26/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$35.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
11/26/2016	Mizuho	Reiterated Rating	Buy	$46.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
11/6/2016	Wedbush	Reiterated Rating	Outperform	$93.00 ➝ $89.00	N/A	i
11/3/2016	BMO Capital Markets	Reiterated Rating	Hold	$35.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
11/3/2016	Mizuho	Lower Price Target	Buy	$64.00 ➝ $46.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
10/27/2016	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$36.00 ➝ $35.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
10/19/2016	Wedbush	Lower Price Target	Outperform	$109.00 ➝ $93.00	N/A	i
10/14/2016	Cowen	Reiterated Rating	Hold		N/A	i
10/7/2016	Brean Capital	Initiated Coverage	Hold		N/A	i Rating by jonathan aschoff at Brean Capital
9/27/2016	Wedbush	Reiterated Rating	Outperform	$109.00	N/A	i Rating by Liana Moussatos at Wedbush
9/26/2016	Jefferies Financial Group	Reiterated Rating	Buy	$74.00 ➝ $60.00	N/A	i
9/21/2016	Wedbush	Reiterated Rating	Outperform	$109.00	N/A	i Rating by Liana Moussatos at Wedbush
9/20/2016	Cowen	Reiterated Rating	Hold		N/A	i
9/7/2016	Cowen	Initiated Coverage	Market Perform		N/A	i
8/5/2016	BMO Capital Markets	Reiterated Rating	Sell	$36.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
8/5/2016	Brean Capital	Reiterated Rating	Hold		N/A	i Rating by Jonathan Aschoff at Brean Capital
8/4/2016	Wedbush	Reiterated Rating	Outperform	$109.00 ➝ $105.00	N/A	i Rating by Liana Moussatos at Wedbush
8/3/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$81.00	N/A	i
8/2/2016	Mizuho	Reiterated Rating	Buy	$64.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
7/28/2016	BMO Capital Markets	Reiterated Rating	Sell		N/A	i Rating by Gary Nachman at BMO Capital Markets
7/20/2016	Mizuho	Reiterated Rating	Buy	$64.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
7/20/2016	Wedbush	Reiterated Rating	Outperform	$105.00	N/A	i
7/19/2016	BMO Capital Markets	Reiterated Rating	Sell	$36.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
7/1/2016	Mizuho	Reiterated Rating	Outperform	$64.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
7/1/2016	Brean Capital	Downgrade	Buy ➝ Hold		N/A	i Rating by Jonathan Aschoff at Brean Capital
6/28/2016	BMO Capital Markets	Initiated Coverage	Underperform	$36.00	N/A	i
6/22/2016	Mizuho	Reiterated Rating	Buy		N/A	i Rating by Irina Rivkind Koffler at Mizuho
6/22/2016	Wedbush	Reiterated Rating	Outperform	$105.00	N/A	i Rating by Liana Moussatos at Wedbush
5/26/2016	Mizuho	Reiterated Rating	Buy		N/A	i Rating by Irina Rivkind Koffler at Mizuho
5/25/2016	Wedbush	Lower Price Target	Outperform	$113.00 ➝ $105.00	N/A	i Rating by Liana Moussatos at Wedbush
5/4/2016	Wedbush	Reiterated Rating	Outperform	$113.00	N/A	i Rating by Liana Moussatos at Wedbush
5/3/2016	Mizuho	Lower Price Target	Buy	$71.00 ➝ $64.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
4/20/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Corey Davis at Canaccord Genuity
4/20/2016	Wedbush	Reiterated Rating	Outperform	$113.00	N/A	i Rating by Liana Moussatos at Wedbush
4/19/2016	Mizuho	Initiated Coverage	Buy	$79.00	N/A	i

(Data available from 4/18/2016 forward)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $63.07

$60.72

$64.88

50 Day Range

MA: $70.38

$66.34

$74.45

52 Week Range

Now: $63.07

$33.47

$80.00

Volume

1,008,258 shs

Average Volume

488,850 shs

Market Capitalization

$2.77 billion

P/E Ratio

22.21

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, Berenberg Bank, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Northland Securities, Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for PCRX.

What is the current price target for Pacira BioSciences?

12 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $77.50, suggesting a possible upside of 22.9%. Barclays PLC has the highest price target set, predicting PCRX will reach $94.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $48.00 for Pacira BioSciences in the next year.
View the latest price targets for PCRX.

What is the current consensus analyst rating for Pacira BioSciences?

Pacira BioSciences currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.

What other companies compete with Pacira BioSciences?

Other companies that are similar to Pacira BioSciences include Johnson & Johnson, Pfizer, Merck & Co., Inc., AbbVie, Eli Lilly and, Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Corcept Therapeutics, Supernus Pharmaceuticals and Endo International.

How do I contact Pacira BioSciences' investor relations team?

Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is 973-254-3560 and its investor relations email address is [email protected] The official website for Pacira BioSciences is www.pacira.com.

NASDAQ:PCRX - Pacira BioSciences Stock Price Target and Predictions

Analyst Price Target for PCRX

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

What is the current price target for Pacira BioSciences?

What is the current consensus analyst rating for Pacira BioSciences?

What other companies compete with Pacira BioSciences?

How do I contact Pacira BioSciences' investor relations team?